BrickBio's engineered RNA and protein-chemistry platform technology enables custom tailoring of any protein with homogenous, site-specific and site-selective bioconjugation modifications, enabling novel classes of biologics with superior therapeutic windows and characteristics such as half-life, dosage, and efficacy.

 

Having validated its precise and unrestricted conjugation capabilities through undisclosed co-development partnerships, the company is building its internal oncology and immunology pipeline by creating unique antibody and bispecific-conjugates while additionally pioneering spatial protein assembly for Precise Protein Origami™.

​

For more information about our pipeline, please use our website contact form.